港股荣昌生物（09995）今日盘中大涨5.01%，引发市场关注。虽然没有直接相关的重大公司新闻，但近期南向资金的持续增持可能是推动股价上涨的主要因素。
根据最新数据，南向资金已连续3日增持荣昌生物。截至6月10日收盘，港股通持有荣昌生物9921.20万股，占流通股的47.57%。在过去5个交易日内，尽管荣昌生物股价下跌5.14%，但港股通仍累计增持232.86万股。更值得注意的是，在近20个交易日内，荣昌生物股价上涨22.32%，期间港股通累计增持高达2125.67万股。
此外，荣昌生物最近的业绩表现也可能支撑了投资者信心。公司2025年一季报显示，主营收入同比上升59.17%，达到5.26亿元；虽然仍然亏损，但归母净利润同比上升27.16%，亏损收窄至2.54亿元。公司主要致力于开发创新生物药，专注于自身免疫疾病、肿瘤疾病和眼科疾病等重大疾病领域，这一定位也可能吸引了投资者的关注。目前，多数机构对荣昌生物持积极态度，近90天内有9家机构给出买入评级。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.